Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice - Gallo, L A; Ward, M S; Fotheringham, A K (Sci Rep, 2016)
et al.